Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis.
OBJECTIVE
To assess whether people who use smokeless tobacco products are at increased risk of myocardial infarction and stroke.


METHODS
Meta-analysis of observational studies from Sweden and the United States.


METHODS
Electronic databases and reference lists.


METHODS
Quantitative estimates of the association between use of smokeless tobacco products and risk of myocardial infarction and stroke among never smokers.


METHODS
Both authors independently abstracted risk estimates and study characteristics. Summary relative risks were estimated on the basis of random effects models.


RESULTS
11 studies, mainly in men, were included. Eight risk estimates were available for fatal myocardial infarction: the relative risk for ever use of smokeless tobacco products was 1.13 (95% confidence 1.06 to 1.21) and the excess risk was restricted to current users. The relative risk of fatal stroke, on the basis of five risk estimates, was 1.40 (1.28 to 1.54). The studies from both the United States and Sweden showed an increased risk of death from myocardial infarction and stroke. The inclusion of non-fatal myocardial infarction and non-fatal stroke lowered the summary risk estimates. Data on dose-response were limited but did not suggest a strong relation between risk of dying from either disease and frequency or duration of use of smokeless tobacco products.


CONCLUSIONS
An association was detected between use of smokeless tobacco products and risk of fatal myocardial infarction and stroke, which does not seem to be explained by chance.
Boffetta
Paolo
P
International Agency for Research on Cancer, Lyon, France. boffetta@iarc.fr
Straif
Kurt
K
D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000209:etiology*; D018570:Risk Assessment; D012307:Risk Factors; D020521:Stroke / Q000209:etiology*; D014030:Tobacco, Smokeless / Q000009:adverse effects*
Control Clin Trials. 1986 Sep;7(3):177-88
3802833
MMWR CDC Surveill Summ. 1994 Nov 18;43(3):1-43
7969014
Epidemiology. 2005 Jan;16(1):12-6
15613940
IARC Monogr Eval Carcinog Risks Hum. 1991;52:1-544
1683674
Epidemiology. 2008 Nov;19(6):794-9
18854704
Int J Epidemiol. 2007 Aug;36(4):789-804
17591642
Eur J Cardiovasc Prev Rehabil. 2004 Apr;11(2):101-12
15187813
Scand J Public Health. 2005;33(4):321-4; discussion 243
16087495
JAMA. 2000 Apr 19;283(15):2008-12
10789670
Stroke. 2003 Jul;34(7):1754-9
12775887
Am J Epidemiol. 2002 Oct 15;156(8):730-7
12370161
Scand J Public Health. 2007;35(6):618-22
17852996
J Am Coll Cardiol. 1999 Nov 15;34(6):1784-90
10577570
J Intern Med. 2002 Nov;252(5):398-404
12528757
Nicotine Tob Res. 2003 Aug;5(4):561-9
12959794
Biometrics. 1994 Dec;50(4):1088-101
7786990
Cancer Causes Control. 2005 May;16(4):347-58
15953977
Harm Reduct J. 2006 Dec 21;3:37
17184539
J Intern Med. 2007 Sep;262(3):360-7
17697157
J Intern Med. 2007 Sep;262(3):351-9
17697156
BMJ. 1992 Nov 21;305(6864):1252-6
1477567